- Home
- ORGO vs ATXS Comparison
ORGO vs ATXS Comparison
Compare ORGO & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORGO
- ATXS
- Stock Information
- Founded
- ORGO 1985
- ATXS 2008
- Country
- ORGO United States
- ATXS United States
- Employees
- ORGO N/A
- ATXS N/A
- Industry
- ORGO Biotechnology: Pharmaceutical Preparations
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- ORGO Health Care
- ATXS Health Care
- Exchange
- ORGO Nasdaq
- ATXS Nasdaq
- Market Cap
- ORGO 459.5M
- ATXS 401.2M
- IPO Year
- ORGO N/A
- ATXS 2015
- Fundamental
- Price
- ORGO $3.21
- ATXS $6.81
- Analyst Decision
- ORGO Strong Buy
- ATXS Strong Buy
- Analyst Count
- ORGO 2
- ATXS 6
- Target Price
- ORGO $5.00
- ATXS $25.67
- AVG Volume (30 Days)
- ORGO 387.6K
- ATXS 244.9K
- Earning Date
- ORGO 02-27-2025
- ATXS 03-03-2025
- Dividend Yield
- ORGO N/A
- ATXS N/A
- EPS Growth
- ORGO N/A
- ATXS N/A
- EPS
- ORGO N/A
- ATXS N/A
- Revenue
- ORGO $455,038,000.00
- ATXS N/A
- Revenue This Year
- ORGO $9.65
- ATXS N/A
- Revenue Next Year
- ORGO $1.57
- ATXS N/A
- P/E Ratio
- ORGO N/A
- ATXS N/A
- Revenue Growth
- ORGO 1.34
- ATXS N/A
- 52 Week Low
- ORGO $2.17
- ATXS $6.64
- 52 Week High
- ORGO $4.57
- ATXS $16.90
- Technical
- Relative Strength Index (RSI)
- ORGO 38.78
- ATXS 31.94
- Support Level
- ORGO $3.42
- ATXS $6.77
- Resistance Level
- ORGO $3.78
- ATXS $7.30
- Average True Range (ATR)
- ORGO 0.15
- ATXS 0.30
- MACD
- ORGO -0.04
- ATXS 0.02
- Stochastic Oscillator
- ORGO 1.72
- ATXS 14.66
About ORGO Organogenesis Holdings Inc.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced wound care, surgical and sports medicine markets. Its product category includes Advanced Wound Care and Surgical and Sports Medicine. It has single operating segment which has regenerative medicine. The company generates maximum revenue from Advanced Wound Care products. Some of its products include PuraPly Antimicrobial, Affinity, NuShield, Apligraf, Dermagraft and others.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.